tetano
Editor, Senior Moderator
Future Microbiol
. 2021 Jan 6.
doi: 10.2217/fmb-2020-0120. Online ahead of print.
Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients
Reza Ghanbari[SUP] 1 [/SUP], Ali Teimoori[SUP] 2 [/SUP], Anahita Sadeghi[SUP] 1 [/SUP], Ashraf Mohamadkhani[SUP] 1 [/SUP], Sama Rezasoltani[SUP] 3 [/SUP], Ebrahim Asadi[SUP] 4 [/SUP], Abolghasem Jouyban[SUP] 5 [/SUP], Susan Cj Sumner[SUP] 6 [/SUP]
Affiliations
Abstract
COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients.
Keywords: COVID-19; SARS-CoV-2; antiviral drugs; drug repurposing.
. 2021 Jan 6.
doi: 10.2217/fmb-2020-0120. Online ahead of print.
Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients
Reza Ghanbari[SUP] 1 [/SUP], Ali Teimoori[SUP] 2 [/SUP], Anahita Sadeghi[SUP] 1 [/SUP], Ashraf Mohamadkhani[SUP] 1 [/SUP], Sama Rezasoltani[SUP] 3 [/SUP], Ebrahim Asadi[SUP] 4 [/SUP], Abolghasem Jouyban[SUP] 5 [/SUP], Susan Cj Sumner[SUP] 6 [/SUP]
Affiliations
- PMID: 33404263
- DOI: 10.2217/fmb-2020-0120
Abstract
COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients.
Keywords: COVID-19; SARS-CoV-2; antiviral drugs; drug repurposing.